Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 6/20 | 0.39 |
| ▸ | NOS1 | P29475 | 6/20 | 0.39 |
| ▸ | NOS2 | P35228 | 6/20 | 0.39 |
| ▸ | FEN1 | P39748 | 12/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 11/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6585159 | 0.81 | NOS1 (0.59) | NOS3NOS1NOS2FEN1ALOX5AP | |
| SCHEMBL221954 | 0.80 | NOS3 (0.58) | KMT2ANOS3NOS1NOS2FEN1 | |
| SCHEMBL6584246 | 0.78 | NOS1 (0.59) | NOS3NOS1NOS2FEN1ALOX5AP | |
| SCHEMBL221140 | 0.78 | NOS3 (0.58) | KMT2ANOS3NOS1NOS2FEN1 | |
| SCHEMBL252012 | 0.77 | NOS1 (0.49) | MEN1LMNAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL218605 | 0.76 | NOS3 (0.59) | KMT2ANOS3NOS1NOS2 | |
| SCHEMBL958723 | 0.76 | NOS1 (0.53) | NOS3NOS1NOS2FEN1ALOX5AP | |
| SCHEMBL6584706 | 0.76 | NOS1 (0.64) | NOS3NOS1NOS2 | |
| SCHEMBL6583707 | 0.74 | FEN1 (0.43) | NOS3NOS1NOS2FEN1ALOX5AP | |
| SCHEMBL251144 | 0.74 | NOS1 (0.42) | NOS3NOS1NOS2FEN1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | PFIZER, INC. | 2003-03-06 | — | — | US | claimed |
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-11-26 | — | — | US | disclosed |
| WO-2018033639-A1 | LACTONE INTERMEDIATES OF NICOTINAMIDE RIBOSIDE AND NICOTINATE RIBOSIDE | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2018-02-22 | — | — | WO | disclosed |
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-07-06 | — | — | US | disclosed |
| US-20150175645-A1 | NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF | GLAXOSMITHKLINE LLC (US) | 2015-06-25 | — | — | US | disclosed |
| EP-1910385-B1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS INC (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-8163908-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120022254-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-8044198-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110009496-A1 | RESVERATROL FORMULATIONS | SIRTRIS PHARMACEUTICAS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| WO-2009158646-A1 | THERAPEUTIC COMPUNDS AND RELATED METHODS OF USE | ELIXIR PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| US-20090163476-A1 | N-Phenyl Benzamide Derivatives as Sirtuin Modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090143376-A1 | Fused Heterocyclic Compounds and Their Use as Sirtuin Modulators | SITRIS PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090099170-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090069301-A1 | Acridine and Quinoline Derivatives as Sirtuin Modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20070248590-A1 | Modulators of CDC2-like kinases (CLKS) and methods of use thereof | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | US | disclosed |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | PFIZER INC. | 2001-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143376-A1 | Fused Heterocyclic Compounds and Their Use as Sirtuin Modulators | SIRT1, SIRT3, SIRT2 | MEN1 4100/4885LMNA 2569/4885MAPT 215/4885 |
| US-20090099170-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | MEN1 3137/4885LMNA 3414/4885MAPT 625/4885 |
| US-20110009496-A1 | RESVERATROL FORMULATIONS | SIRT1, SIRT5, SIRT2 | MEN1 936/4885LMNA 1138/4885MAPT 261/4885 |
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | NNT, CS, ME2 | MEN1 1467/4885LMNA 515/4885MAPT 2354/4885 |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | GRIN3A, GRIN1, CHRNA10 | MEN1 3328/4885LMNA 1289/4885MAPT 741/4885 |
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | NOS1, PTGS1, NOS2 | MEN1 3437/4885LMNA 3347/4885MAPT 746/4885 |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | EP300, KAT2A, KAT6B | MEN1 2682/4885LMNA 2234/4885MAPT 1946/4885 |
| US-20150175645-A1 | NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF | SIRT1, NAMPT, SIRT2 | MEN1 2651/4885LMNA 2093/4885MAPT 783/4885 |
| US-20090069301-A1 | Acridine and Quinoline Derivatives as Sirtuin Modulators | SIRT1, SIRT3, SIRT2 | MEN1 3703/4885LMNA 3404/4885MAPT 207/4885 |
| US-20090163476-A1 | N-Phenyl Benzamide Derivatives as Sirtuin Modulators | SIRT1, SIRT3, SIRT2 | MEN1 4043/4885LMNA 1903/4885MAPT 847/4885 |
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | NNT, CS, ME2 | MEN1 1467/4885LMNA 515/4885MAPT 2354/4885 |
| US-20120022254-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | MEN1 3137/4885LMNA 3414/4885MAPT 625/4885 |
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | MEN1 3137/4885LMNA 3414/4885MAPT 625/4885 |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | GRIN2C, GRIN2A, CNR2 | MEN1 988/4885LMNA 1201/4885MAPT 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.